68 filings
Page 2 of 4
8-K
emcg03fwq
8 Aug 23
23andMe Reports FY2024 First Quarter Financial Results
4:10pm
8-K
3tdnkrynm
9 Jun 23
Cost Associated with Exit or Disposal Activities
4:05pm
8-K
0e9llkkwucko
25 May 23
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
4:08pm
8-K
sk78lzt 0fdih2w4
17 Apr 23
Regulation FD Disclosure
4:10pm
8-K
r8i1nqxic a48z
14 Apr 23
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
4:08pm
8-K
ml0h6ko7p jyf
8 Feb 23
23andMe Reports FY2023 Third Quarter Financial Results
4:09pm
8-K
ref8n mvxhp8pnh
6 Feb 23
Other Events
4:53pm
8-K
73y 1s7f53wyo7a8v
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
nc8zqn 99xwxctimcia5
9 Nov 22
Investor Presentation November 2022
7:30am
8-K
ukrqa 7ijv9aenc3
7 Nov 22
23andMe Reports FY2023 Second Quarter Financial Results
4:06pm
8-K
ekm9rj 7uqorpy
4 Nov 22
Other Events
4:06pm
8-K
tw95aya
27 Oct 22
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
7:32am
8-K
3e7mu
31 Aug 22
Submission of Matters to a Vote of Security Holders
7:13pm
8-K/A
rvlmxpxivxzu9v1hon49
30 Aug 22
Departure of Directors or Certain Officers
4:05pm
8-K
b4nylgdqr uua
19 Aug 22
Departure of Directors or Certain Officers
8:02am
8-K
uvb1 ak7q5t
18 Aug 22
Investor Presentation August 2022
4:06pm
8-K
2mq2en
8 Aug 22
23andMe Reports FY2023 First Quarter Financial Results
4:14pm
8-K
jfr2d
13 Jun 22
Departure of Directors or Certain Officers
4:05pm
8-K
m8lv3rrdz4jkczh
26 May 22
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
4:02pm
8-K
yxbvue89 ft
13 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:57pm